55 results on '"Khanna, Dinesh"'
Search Results
2. Interstitial pneumonia with autoimmune features (IPAF): a clinical entity?
3. Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF)
4. Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)
5. AB0695 LONG-TERM OUTCOMES OF AFRICAN AMERICAN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
6. SAT0279 MULTICENTER DOUBLE-BLIND, PROOF-OF-CONCEPT, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RIOCIGUAT IN SYSTEMIC SCLEROSIS-ASSOCIATED DIGITAL ULCERS (RESCUE)
7. FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD’S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY
8. OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS— RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
9. OP0183 EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY
10. THU0354 MACHINE LEARNING CLASSIFICATION OF SKIN GENE EXPRESSION IDENTIFIES A SUBSET OF SYSTEMIC SCLEROSIS PATIENTS MOST LIKELY TO SHOW CLINICAL IMPROVEMENT IN RESPONSE TO ABATACEPT
11. OP0245 PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC
12. FRI0310 UNIVERSITY OF CALIFORNIA LOS ANGELES SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL TRACT 2.0 REFLUX-SCALE ASSOCIATES WITH IMPAIRED ESOPHAGEAL SCINTIGRAPHY FINDINGS IN SYSTEMIC SCLEROSIS
13. FRI0327 EVALUATION OF AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE INDEX IN SYSTEMIC SCLEROSIS IN A PHASE II TRIAL OF ABATACEPT VS. PLACEBO
14. AB0966 PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018
15. OP0069 PERFORMANCE OF AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (CRISS) SCORE IN PHASE 2 TRIAL OF LENABASUM IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSS)
16. Randomized controlled trial of abituzumab in systemic sclerosis-associated interstitial lung disease
17. Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study
18. Developing A Disease Activity And Therapeutic Response Index In Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Consensus On Domains
19. Predictive Value Of Non-Invasive Tests For The Diagnosis Of Scleroderma-Associated Pulmonary Hypertension: Pharos Registry
20. Exercise Induced Pulmonary Hypertension In Systemic Sclerosis And Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
21. Predicting Treatment Outcomes And Responder Subsets In Scleroderma-Related Interstitial Lung Disease
22. Exercise Induced Pulmonary Hypertension Associated With Systemic Sclerosis: Four Distinct Entities
23. Validation Of A Computer Aided Quantitative Fibrosis Score In Systemic Sclerosis Patients
24. A Distinctive Pulmonary Vasculopathy: Quantitative Histological Analysis distinguishes Systemic Sclerosis & Idiopathic Pulmonary Fibrosis From Idiopathic Pulmonary Hypertension
25. Open Labeled Study Of Imatinib Mesylate (Gleevec) In The Treatment Of Systemic Sclerosis- Associated Active Interstitial Lung Disease (SSc-ILD): Preliminary Results
26. Survival In Pulmonary Hypertension Associated With Scleroderma-Specturm Disease: A Single Center Experience
27. Optimization of bottom antireflective coating materials for dual damascene process.
28. Performance impact of novel polymeric dyes in photoresist applications
29. Bottom antireflective coatings for ArF, KrF, and i-line applications: a comparison of theory, design, and lithographic aspects
30. Effect of cresol monomers in three-component novolak resin on photolithographic performance
31. Process and performance optimization of bottom antireflective coatings: II
32. Performance of 193-nm resists based on alicyclic methacrylate and cyclo-olefin systems
33. Process and performance optimization of bottom antireflective coatings
34. Novolak resin for ultrafast high-resolution positive i-line photoresist compositions
35. Process effects resulting from conversion to a safe-solvent organic BARC
36. Lithographic performance of a dry-etch stable methacrylate resist at 193 nm
37. Monitoring and controlling synthesis of bottom antireflective coating materials by in-situ FT-IR technique
38. Isolation of novolak resin at low temperature
39. Process and performance optimization of bottom antireflective coatings: II.
40. Effect of cresol monomers in three-component novolak resin on photolithographic performance.
41. Performance impact of novel polymeric dyes in photoresist applications.
42. Novel DNQ PACs for high-resolution i-line lithography
43. Process effects resulting from conversion to a safe-solvent organic BARC.
44. Novolak resin for ultrafast high-resolution positive i-line photoresist compositions.
45. Process and performance optimization of bottom antireflective coatings.
46. Synthesis of novolac resin by acid removal after condensation (ARAC) process.
47. Novel polymeric dyes for bottom antireflective coatings.
48. Use of highly absorptive azo dyes in photoresist coatings.
49. Isolation of novolak resin at low temperature.
50. Novel DNQ PACs for high-resolution i-line lithography.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.